Astellas Pharma Inc
TSE:4503
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 446
1 828
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Astellas Pharma Inc
Astellas Pharma Inc
Cost of Revenue
Astellas Pharma Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Astellas Pharma Inc
TSE:4503
|
Cost of Revenue
-¥383.6B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cost of Revenue
-¥1.5T
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-12%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cost of Revenue
-¥420B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-6%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cost of Revenue
-¥648.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Cost of Revenue
-¥59.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
3%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cost of Revenue
-¥337.2B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
|
Astellas Pharma Inc
Glance View
Astellas Pharma Inc., a prominent player in the global pharmaceutical industry, has a clear mission: to improve the health of people around the world through innovative technologies and high-quality products. Founded in 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established itself as a leader in areas such as urology, oncology, immunology, and neuroscience. With strong research and development capabilities, the company invests heavily in developing groundbreaking therapies that address unmet medical needs, positioning itself at the forefront of advancements in health sciences. Astellas prides itself on its commitment to sustainability, ensuring that its operations positively impact society while delivering substantial value to shareholders. For investors, Astellas represents a compelling opportunity, given its strong financial footing and robust product pipeline. The company boasts a diverse portfolio with several key blockbuster drugs contributing to its steady revenue stream, alongside a promising array of candidates in clinical trials. Furthermore, Astellas actively pursues strategic partnerships and acquisitions to bolster its R&D initiatives and expand its global reach. With a focus on maximizing shareholder value through disciplined financial management and a strategic approach to innovation, Astellas Pharma is not just navigating the complexities of the pharmaceutical landscape; it is shaping the future of healthcare, making it a noteworthy consideration for investors looking for growth in the biotech sphere.
See Also
What is Astellas Pharma Inc's Cost of Revenue?
Cost of Revenue
-383.6B
JPY
Based on the financial report for Jun 30, 2024, Astellas Pharma Inc's Cost of Revenue amounts to -383.6B JPY.
What is Astellas Pharma Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-2%
Over the last year, the Cost of Revenue growth was -43%. The average annual Cost of Revenue growth rates for Astellas Pharma Inc have been -16% over the past three years , -6% over the past five years , and -2% over the past ten years .
You don't have any saved screeners yet
